Sarepta Therapeutics, Inc. SRPT Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Efficiency | ||||||
| Asset turnover | 0.7×+0.1× | 0.6×— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 4.6×+2.3× | 2.3×-0.6× | 3×+0.1× | 2.9×-1.1× | 4×-0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.1× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Valuation | ||||||
| Market capitalization | $2.28B+1.3% | $2.26B+11.8% | $2.02B+8.1% | $1.87B-69.9% | $6.19B-46.7% | |
| Price / sales | 1×0.0× | 1×— | —— | —— | —— | |
| Price / book | 1.5×-0.5× | 2×+0.4× | 1.5×+0.2× | 1.4×-4.0× | 5.4×-2.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Sarepta Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Sarepta Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
